

## Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- planning to receive Immune Checkpoint Therapy (ICI) for a solid tumor cancer - if received prior ICI-based therapy must have completed it at least 180 days before starting the study - must be able to complete Patient-Reported Outcome (PRO) forms in English, Spanish, or French - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete inclusion and exclusion criteria

### Conditions & Interventions

#### Conditions:

Cancer

#### Keywords:

cancer, ICI, Immune Checkpoint Therapy, solid tumor

### More Information

**Description:** This study looks at how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments

**Study Contact:** Kristen Nelson - [knelson65@fairview.org](mailto:knelson65@fairview.org)

**Principal Investigator:** Puneet Cheema

**IRB Number:** MMCORC082

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.